Andrew D. Moin's most recent trade in SAB Biotherapeutics Inc was a trade of 228,500 Series B Convertible Preferred Stock done . Disclosure was reported to the exchange on July 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics Inc | Andrew D. Moin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 228,500 | 228,500 | - | - | Series B Convertible Preferred Stock | |
| SAB Biotherapeutics Inc | Andrew D. Moin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 228,500 | 228,500 | - | - | Warrants (right to buy) | |
| SAB Biotherapeutics Inc | Andrew D. Moin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 114,250 | 114,250 | - | - | Warrants (right to buy) |